PLoS ONE (Jan 2016)

Establishment of Protocols for Global Metabolomics by LC-MS for Biomarker Discovery.

  • Daisuke Saigusa,
  • Yasunobu Okamura,
  • Ikuko N Motoike,
  • Yasutake Katoh,
  • Yasuhiro Kurosawa,
  • Reina Saijyo,
  • Seizo Koshiba,
  • Jun Yasuda,
  • Hozumi Motohashi,
  • Junichi Sugawara,
  • Osamu Tanabe,
  • Kengo Kinoshita,
  • Masayuki Yamamoto

DOI
https://doi.org/10.1371/journal.pone.0160555
Journal volume & issue
Vol. 11, no. 8
p. e0160555

Abstract

Read online

Metabolomics is a promising avenue for biomarker discovery. Although the quality of metabolomic analyses, especially global metabolomics (G-Met) using mass spectrometry (MS), largely depends on the instrumentation, potential bottlenecks still exist at several basic levels in the metabolomics workflow. Therefore, we established a precise protocol initially for the G-Met analyses of human blood plasma to overcome some these difficulties. In our protocol, samples are deproteinized in a 96-well plate using an automated liquid-handling system, and conducted either using a UHPLC-QTOF/MS system equipped with a reverse phase column or a LC-FTMS system equipped with a normal phase column. A normalization protocol of G-Met data was also developed to compensate for intra- and inter-batch differences, and the variations were significantly reduced along with our normalization, especially for the UHPLC-QTOF/MS data with a C18 reverse-phase column for positive ions. Secondly, we examined the changes in metabolomic profiles caused by the storage of EDTA-blood specimens to identify quality markers for the evaluation of the specimens' pre-analytical conditions. Forty quality markers, including lysophospholipids, dipeptides, fatty acids, succinic acid, amino acids, glucose, and uric acid were identified by G-Met for the evaluation of plasma sample quality and established the equation of calculating the quality score. We applied our quality markers to a small-scale study to evaluate the quality of clinical samples. The G-Met protocols and quality markers established here should prove useful for the discovery and development of biomarkers for a wider range of diseases.